Cardiac Function and Metabolism in Young Adults Born Premature (PET-MRI) (PET-MRI)

February 2, 2021 updated by: University of Wisconsin, Madison

Cardiac Function and Metabolism in Young Adults Born Premature

The purpose of this research is to determine the effect of premature birth on later heart function and metabolism.

Study Overview

Detailed Description

The purpose of this study is to determine the effects of premature birth on cardiac function, cardiac metabolism, and oxidative stress in a cohort of young adults born prematurely using cardiac positron emission tomography/magnetic resonance imaging and mitochondrial respiration studies.

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • UW Madison

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • National Lung Project Cohort only- birth weight <1500g and a gestational age <36 weeks
  • Adults born preterm (Non-National Lung Project) only- gestational age ≤32 weeks OR birth weight ≤ 3lbs 5oz
  • Healthy Controls only- No personal history of known cardiovascular or pulmonary disease

Exclusion Criteria:

  • Metabolic Disorders that would affect Fludeoxyglucose uptake
  • Contraindications to positron emission tomography and/or magnetic resonance imaging
  • Pregnancy, if a female of child-bearing potential
  • A personal history of Type I or Type II diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Preterm

Participants born premature either registered on the National Lung Project (currently in their late twenties) or not registered on the National Lung Project Cohort (current age ranges 18-35 years).

All the participants in this group will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.

Subjects will undergo an electrocardiogram to ensure sinus rhythm
Subjects will undergo Spirometry and Plethysmography
Subjects will undergo positron emission tomography to detect images of the heart
Subjects will undergo positron magnetic resonance imaging to detect images of the heart
Placebo Comparator: Term - Healthy Controls
Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
Subjects will undergo an electrocardiogram to ensure sinus rhythm
Subjects will undergo Spirometry and Plethysmography
Subjects will undergo positron emission tomography to detect images of the heart
Subjects will undergo positron magnetic resonance imaging to detect images of the heart

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiac Glucose Uptake During Normoxic Rest (µg/Min)
Time Frame: Visit 1 (1 day)
Cardiac glucose uptake will be measured via 18F-fluorodeoxyglucose (FDG) PET-MRI.
Visit 1 (1 day)
Change in Glucose Uptake From Normoxia to Hypoxia (µg/Min)
Time Frame: Visit 1 (1 day)
Cardiac glucose uptake will be measured via 18F-fluorodeoxyglucose (FDG) PET-MRI.
Visit 1 (1 day)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kara N Goss, MD, The University of Wisconsin School of Medicine and Public Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 20, 2017

Primary Completion (Actual)

February 26, 2020

Study Completion (Actual)

February 26, 2020

Study Registration Dates

First Submitted

August 8, 2017

First Submitted That Met QC Criteria

August 8, 2017

First Posted (Actual)

August 10, 2017

Study Record Updates

Last Update Posted (Actual)

February 4, 2021

Last Update Submitted That Met QC Criteria

February 2, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2017-0238
  • A534285 (Other Identifier: UW Madison)
  • SMPH/MEDICINE/MEDICINE*P (Other Identifier: University of Wisconsin-Madison)
  • UL1TR000427 (U.S. NIH Grant/Contract)
  • Protocol Version 4/23/2019 (Other Identifier: UW Madison)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infant,Premature

Clinical Trials on Electrocardiogram

3
Subscribe